Risk of pancreatic malignancy and mortality in branch-duct IPMNs undergoing surveillance: A systematic review and meta-analysis

6533b829fe1ef96bd128ae26

RESEARCH PRODUCT

Risk of pancreatic malignancy and mortality in branch-duct IPMNs undergoing surveillance: A systematic review and meta-analysis

Carlos Fernandez-del Castillo Gabriele Capurso Gianfranco Delle Fave Calogero Cammà Stefano Crippa Massimo Falconi

subject

Oncology medicine.medical_specialty Pancreatic malignancy endocrine system diseases medicine.medical_treatment Non-operative management Gastroenterology Malignant transformation 03 medical and health sciences Pancreatectomy 0302 clinical medicine Risk Factors Internal medicine Pancreatic cancer medicine Humans Watchful Waiting Hepatology business.industry Follow-up Mortality rate Pancreatic Ducts Gastroenterology Pancreatic cancer medicine.disease Pancreatic Neoplasms Cell Transformation Neoplastic 030220 oncology & carcinogenesis Meta-analysis Pancreatectomy Very low risk 030211 gastroenterology & hepatology follow-up; non-operative management; pancreatectomy; pancreatic cancer Neoplasms Cystic Mucinous and Serous business Watchful waiting Carcinoma Pancreatic Ductal

description

Abstract Background Safety of non-operative management for low-risk branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) is debated. Aim To perform a systematic review/meta-analysis to determine their risk of developing pancreatic malignancy and of pancreatic malignancy-related deaths. Methods A MEDLINE search was performed and methodology was based on PRISMA statement. Incidence rates of overall pancreatic malignancy, malignant BD-IPMN, IPMN-distinct PDAC, and of pancreatic malignancy-related death rates were calculated by dividing the total number of events by the total number of person-years (pyrs) of follow-up. Heterogeneity was determined by I2 statistic. Results 20 studies including 2177 patients were included. Mean follow-up ranged from 29.3 to 76.7 months. Overall, 82 patients (3.7%) developed a pancreatic malignancy with a pooled estimate rate of 0.007/pyrs (I2 = 32.8%). The pooled estimate rate of malignant IPMN was 0.004/pyrs (I2 = 40.8%), and the pooled estimate rate of distinct PDAC 0.002/pyrs (I2 = 0%). The rate of death due to pancreatic malignancy during follow-up was 0.9%, with an overall pooled estimate rate of death of 0.002/pyrs (I2 = 0%). Conclusion Non-operative management of low-risk BD-IPMN is safe, with a very low risk of malignant transformation of IPMN and of distinct PDAC. The rate of pancreatic malignancy-related mortality is low, particularly when compared with the mortality of pancreatic surgery.

year	journal	country	edition	language
2016-01-01	Digestive and Liver Disease

https://doi.org/10.1016/j.dld.2016.02.003